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Abstract
Distal biliary strictures (DBS) are common and may be caused by both malignant and be-
nign pathologies. While endoscopic procedures play a major role in their management, a
comprehensive review of the subject is still lacking. Our consensus statements were formu-
lated by a group of expert Asian pancreatico-biliary interventional endoscopists, following
a proposal from the Digestive Endoscopy Society of Taiwan, the Thai Association for Gas-
trointestinal Endoscopy, and the Tokyo Conference of Asian Pancreato-biliary Interven-
tional Endoscopy. Based on a literature review utilizing Medline, Cochrane library, and
Embase databases, a total of 19 consensus statements on DBS were made on diagnosis, en-
doscopic drainage, benign biliary stricture, malignant biliary stricture, and management of
recurrent biliary obstruction and other complications. Our consensus statements provide
comprehensive guidance for the endoscopic management of DBS.
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Introduction
Distal biliary strictures (DBS) are common and may be caused by
both malignant and benign pathologies. While endoscopic proce-
dures play a major role in their management, a comprehensive re-
view of the subject is still lacking, which has impact on diagnosis
(imaging and pathological) and treatment (indications, procedure
options, and outcomes). The consensus statements presented here
were formulated following a literature review and discussion
among international experts. The aim is to provide comprehensive
guidance for the endoscopic management of DBS.
Methods
The consensus statements were formulated by a group of expert
Asian pancreatico-biliary interventional endoscopists, some of
whom perform interventional radiology procedures and operative
surgical procedures in their routine clinical practice, following a
proposal from the Digestive Endoscopy Society of Taiwan
(DEST), the Thai Association for Gastrointestinal Endoscopy
(TAGE), and the Tokyo Conference of Asian Pancreato-biliary
Interventional Endoscopy (T-CAP).
Based on a literature review utilizing Medline, Cochrane library,
and Embase databases, first draft clinical questions (CQs) were de-
veloped by a planning panel (HI, RR, HPW, IY, YN, and HK).
These first draft CQs were discussed via the internet and revised
by each author. A face-to-face meeting was conducted in June
2017 in Tokyo, Japan. After further discussion and revision, the
statements were voted on by all attendees (YN, HI, HPW, RR,
CK, IY, HK, JHM, JL, SL, TR, DWS, DKL, DM, FD, WL,
PVD, MA, AI, AK, MK, SR, and TF). The evidence level and rec-
ommendation grade were evaluated using the evidence leveling
system (Table 1).1 The discussion continued until an agreement
of greater than 80% was achieved for recommendation Level A
or B. Finally, after voting, a total of 19 consensus statements were
agreed upon. The second draft of consensus statements was pre-
sented for open discussion at Asia Pacific Digestive Week
(APDW) in September 2017 in Hong Kong. Subsequently, the
revised statements were discussed among the faculty members
via the internet. The resultant manuscript was evaluated by three
expert endoscopists (MW, TI, and BD) and was finalized by each
author.
Definition of distal biliary stricture. Numerous studies
have reported on DBS, but anatomical definitions vary. The most
commonly used definitions used include stenosis of the distal third
of the extrahepatic bile duct,2 the intrapancreatic portion of the
common bile duct, or the distal half of the extrahepatic bile duct.3
Some papers on the subject do not provide a definition. As the fo-
cus of our consensus statements is on endoscopic management and
the intra-pancreatic portion4 of the common bile duct cannot be
determined on endoscopic retrograde cholangio-pancreatography
(ERCP), we have excluded the use of the intrapancreatic bile duct
as a definition. There was a debate during the face-to-face meeting,
but there were no clear reasons to select one over the other. Hence,
we define DBS as abnormal narrowing of the distal half, which in-
cludes the distal third, of the extrahepatic bile duct.
Consensus statements
Diagnosis
CQ1. What strategy is recommended for diagnosis of dis-
tal biliary strictures?.
Statement 1-1. The diagnostic strategy for evaluating a DBS is
determined by the possible etiology, clinical features, abnormal
liver biochemistries, and/or cross-sectional imaging.
Evidence level: D
Recommendation: 1
Agreement: A, 0%; B, 100%; C, 0%; D, 0%
Statement 1-2. In patients with DBS, ERCP and/or endoscopic
ultrasound (EUS) are often helpful in establishing the etiology.
Evidence level: A
Recommendation: 1
Agreement: A, 96%; B, 4%; C, 0%; D, 0%
First of all, detailed history taking and physical examination
should be performed. Painless jaundice with Courvoisier’s sign5
and a previous history of malignancy raises the possibility of ma-
lignant biliary stricture (MBS). Meanwhile, a history of pancreati-
tis in heavy drinkers suggests the presence of chronic pancreatitis
as a cause of biliary stricture. In addition to hepatobiliary enzymes,
some serum markers may help in the diagnosis of DBS. Serum
carbohydrate antigen (CA) 19–9 is a tumor marker useful for
pancreato-biliary cancer with a sensitivity of 70–80% in pancre-
atic cancer and 50–80% in biliary tract cancer.6,7 However,
CA19–9 increases in the presence of cholestasis and cholangitis,
and false positive results are possible in cases with DBS. IgG4 re-
lated diseases including autoimmune pancreatitis can be a cause of
DBS and serum IgG4 level is high in about 80% of autoimmune
pancreatitis.
Table 1 Quality of evidence, classification of recommendations and




A (strong) Strongly confident in the effect of estimate.
B (moderate) Moderately confident in the effect of estimate.
C (weak) Confidence in the effect of estimate is limited.
D (very weak) Almost no confidence in the effect of estimate.
Classification of the recommendation
1 Strong recommendation
2 Weak recommendation
Voting on the recommendation
A Accept completely
B Accept with some reservations
C Accept with major reservations
D Reject with reservations
E Reject completely
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The diagnostic strategy for evaluating DBS should take into
account the presence of jaundice or abnormal liver biochemistry,
findings of cross-sectional imaging, and probability of resectabil-
ity, if a tumor is detected (Fig. 1). When a pancreatic tumor
causing DBS is noted on cross-sectional imaging, EUS-guided
fine needle aspiration (EUS-FNA) is helpful in establishing a
tissue diagnosis. Notably, EUS may detect occult periampullary
tumors in patients who present with DBS but without a mass
on cross-sectional imaging.8,9 In jaundiced patients, ERCP is
an appropriate first-line procedure as both diagnostic and thera-
peutic maneuvers can be performed including transpapillary
brush cytology or forceps biopsy and biliary drainage. The diag-
nostic yield of EUS-guided and transpapillary tissue sampling is
discussed later in CQ3. In summary, the diagnostic strategy
should be directed by the presence of jaundice and initial
cross-sectional imaging.
CQ2. What is the role of cross-sectional imaging?.
Statement 2. Contrast-enhanced computed tomography (CT) or
magnetic resonance imaging (MRI) is necessary for the detection




Agreement: A, 100%; B, 0%; C, 0%; D, 0%
Cross-sectional imaging such as contrast-enhanced CT or MRI
is commonly utilized in clinical practice to assess patients with
DBS. Both CT and MRI have high diagnostic accuracy for identi-
fication and characterization of primary lesions10,11 and to deter-
mine resectability of malignancy.11,12 Therefore, multiphasic
contrast-enhanced CT or MRI should be performed in the initial
evaluation of patients with DBS prior to invasive procedures such
as EUS or ERCP. CT and MRI confer the additional advantage of
potentially detecting distant metastasis.
CQ3. What is the optimal approach for tissue acquisi-
tion?.
Statement 3. ERCP-guided tissue acquisition should be attempted
when biliary drainage is required. EUS-FNA is preferred when
cross-sectional imaging reveals a mass associated with the stricture
or when ERCP-guided tissue acquisition is unsuccessful.
Evidence level: A
Recommendation: 1
Agreement: A, 100%; B, 0%; C, 0%; D, 0%
EUS-FNA provides both high sensitivity and specificity in diag-
nosing a pancreatic mass. In a meta-analysis, the pooled sensitivity
and specificity of EUS-FNA in correctly diagnosing pancreatic
masses was 86.8% (95% confidence interval, CI, [85.5, 87.9])
and 95.8% (95% CI [94.6, 96.7]).13 In cases with biliary stricture,
Figure 1 The diagnostic strategy and tissue sampling approach for a distal biliary stricture. *EUS-FNA is recommended for an extrinsic biliary stricture
and POCS for an intrinsic biliary stricture. CT, computed tomography; ERCP, endoscopic retrograde cholangio-pancreatography; EUS, endoscopic ultra-
sound; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; MRI, magnetic resonance imaging; POCS, peroral cholangioscopy.
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the sensitivity and specificity of EUS-FNA for characterizing the
biliary stricture was 80% and 97%, respectively.14 The diagnostic
yield is lower in the absence of a mass,15 but EUS can detect small
(<2 cm) pancreatic lesions. In one retrospective study, the sensi-
tivity of EUS-FNA was 87.3% in pancreatic neoplasm without a
definitive mass on CT.16
In cases requiring endoscopic biliary drainage, a tissue diagno-
sis may be made during ERCP. In a meta-analysis,17 the pooled
sensitivity and specificity of brush cytology for the diagnosis of
a MBS was 45% (95% CI [40%, 50%]) and 99% (95% CI [98%,
100%]), respectively. Intraductal forceps biopsies had a pooled
sensitivity and specificity of 48.1% (95% CI [42.8%, 53.4%])
and 99.2% (95% CI [97.6%, 99.8%]), respectively. In another
study, the sensitivity of transpapillary tissue sampling during
ERCP was 49% compared with 75% by EUS-FNA.18 The cause
of the biliary stricture also affects diagnostic yield.19 Diagnostic
accuracy of ERCP-guided tissue sampling was 81.8% and 67.8%
in intrinsic and extrinsic biliary strictures (P = 0.023), respectively.
As most DBS are associated with obstructive jaundice or
cholangitis, transpapillary biliary drainage is usually necessary to
relieve symptoms. Therefore, we recommend that transpapillary
tissue sampling should be attempted at the time of biliary drainage
during ERCP. If transpapillary tissue sampling is non-diagnostic or
if early biliary drainage is unnecessary, we recommend EUS-FNA
to secure the pathological diagnosis, especially when the DBS is
associated with a mass. Despite concerns that the presence of a bil-
iary stent may compromise the accuracy of EUS imaging, most
studies have reported that an indwelling biliary stent does not ad-
versely affect the diagnostic yield of EUS-FNA.20 Alternatively,
EUS and ERCP may be performed in a single session for evalua-
tion of obstructive jaundice as a result of a pancreatic mass.21,22
While EUS-FNA can provide a histopathological diagnosis with
high sensitivity, biliary drainage may be effected via ERCP in
the same session. With this single session approach, EUS-FNA
may be performed without interference from an indwelling stent,
and repeated sedation can be avoided. Our proposal for the patho-
logical diagnostic approach is shown in Figure 1. The diagnostic
approach, with either transpapillary tissue sampling during ERCP
or EUS-FNA, should also be determined according to local exper-
tise and/or the costs associated with each procedure and the requi-
site devices.
CQ4. What are the roles of advanced imaging modalities
for distal biliary stricture?.
Statement 4. Per-oral cholangioscopy (POCS) and intraductal ul-
trasonography may improve the characterization of DBS.
Evidence level: C
Recommendation: 2
Agreement: A, 50%; B, 45%; C, 5%; D, 0%
The addition of POCS and intraductal ultrasonography (IDUS)
during ERCP may increase diagnostic yield. In a prospective study
of 26 cases of indeterminate biliary stricture, cholangioscopy-
guided biopsy using biopsy forceps dedicated for POCS provided
higher sensitivity and accuracy (76.5% and 84.6%) compared with
brush cytology (5.8% and 38.5%) and conventional forceps
biopsies (29.4% and 53.9%).23 Notably, in another prospective
study, the accuracy of POCS-directed biopsies was 82% in 33 pa-
tients in whom ERCP-guided brushing or biopsy was inconclu-
sive.24 Recently, a digital, single operator cholangioscope has
been introduced,25,26 which provides improved intraductal visual-
ization and maneuverability. It has shown promising results, with
sensitivity and specificity in excess of 80% in both visual inspec-
tion and cholangioscopy-guided biopsy. As we discussed in
CQ3, however, the indication of POCS should be considered after
EUS because EUS-FNA showed better diagnostic yield in the ex-
trinsic stricture as a result of a pancreatic mass. The EUS first ap-
proach would reduce the need, cost, and adverse events (AEs) of
POCS.27 Furthermore, maneuverability and visualization of POCS
are often limited in the very DBS because of the unstable scope
position. In a retrospective analysis of 397 cases with indetermi-
nate biliary stricture, IDUS was useful in predicting malignancy
with a sensitivity, specificity, and accuracy of 93%, 89%, and
91%, respectively.28 However, most studies on the utility of IDUS
and POCS included both hilar and DBS and did not evaluate their
specific use in DBS. Probe-based confocal laser endomicroscopy,
which can provide in vivo imaging during ERCP, is reportedly
useful for diagnosing indeterminate biliary strictures, but its role
in clinical practice is yet to be determined because of poor inter-
observer agreement and cost.29
Endoscopic drainage
CQ5. When is endoscopic biliary drainage indicated?.
Statement 5–1. Endoscopic biliary drainage is indicated for the
treatment of cholangitis and for relief of cholestasis.
Evidence level: A
Recommendation: 1
Agreement: A, 95%; B, 0%; C, 5%; D, 0%
Statement 5–2. Endoscopic stenting is generally considered to be
primary therapy for benign biliary strictures (BBS).
Evidence level: A
Recommendation: 1
Agreement: A, 90%; B, 5%; C, 5%; D, 0%
Statement 5–3. Endoscopic stenting is the preferred therapy for
palliation of cholestasis in unresectable MBS.
Evidence level: A
Recommendation: 1
Agreement: A, 68%; B, 32%; C, 0%; D, 0%
Benign and malignant pathologies may cause DBS. Whereas the
etiology of DBS should be sought in every patient, not all patients
with DBS require biliary drainage. Where there is no evidence of
cholestasis or cholangitis, drainage may not be necessary. Biliary
drainage should be performed if there is cholangitis and/or chole-
stasis to relieve the associated clinical symptoms. There are a num-
ber of treatment options for biliary drainage: Surgical bypass,
percutaneous transhepatic biliary (or gallbladder) drainage, and
endoscopic biliary drainage, either by the transpapillary route
International consensus for DBS Y Nakai et al.
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during ERCP or EUS guided. In general, endoscopic biliary drain-
age is considered less invasive and affords a better quality of life.
When biliary drainage is indicated, endoscopic stenting is consid-
ered the initial technique of choice. The indication for endoscopic
biliary drainage differs between benign and malignant etiologies.
For BBS, such as post-surgical strictures and strictures secondary
to chronic pancreatitis, endoscopic biliary stenting is performed
for the relief of cholestasis and to dilate the stricture. For patients
with obstructive jaundice due to benign pathologies like autoim-
mune pancreatitis or lymphoma, in whom the stricture is expected
to fully resolve with medical management, biliary drainage may
not be required. In patients with unresectable malignant DBS,
however, endoscopic biliary stenting is performed primarily for
palliation. For resectable malignant DBS, please see CQ10.
CQ6. What type of endoscopic biliary drainage is available
for distal biliary stricture?.
Statement 6. ERCP with transpapillary stenting is the mainstay of
biliary drainage; EUS-guided biliary drainage (EUS-BD) is an al-
ternative endoscopic treatment when ERCP is not possible.
Evidence level: A
Recommendation: 1
Agreement: A, 68%; B, 32%; C, 0%; D, 0%
In patients with DBS, biliary drainage may be achieved during
ERCP or percutaneous transhepatic biliary drainage (PTBD).
ERCP is preferred over PTBD as no fluid or electrolyte losses oc-
cur and cutaneous puncture-site pain is avoided. ERCP, in expert
hands, is also associated with significantly higher clinical success
and requires fewer re-interventions.30,31 However, difficult biliary
cannulation at ERCP, which accounts for up to 10% of all ERCPs,
is associated with a higher risk of ERCP-related complications.32
In addition, ERCP may not be technically possible in the presence
of duodenal obstruction and surgically altered anatomy. PTBD has
long been utilized as an alternative non-endoscopic drainage
method in cases with failed ERCP and is still the standard alterna-
tive technique in many centers. EUS-guided biliary drainage
(EUS-BD) has been reported as an alternative modality after failed
ERCP where expertise is available33,34; this is further discussed
in CQ8.
CQ7. How should we follow patients after biliary stent
placement?.
Statement 7–1. In patients with benign DBS, ERCP with planned
stent exchange or removal is recommended.
Evidence level: C
Recommendation: 2
Agreement: A, 100%; B, 0%; C, 0%; D, 0%
Statement 7–2. In patients with malignant DBS treated with a
metal stent, endoscopic re-intervention is performed on demand.
Evidence level: C
Recommendation: 2
Agreement: A, 100%; B, 0%; C, 0%; D, 0%
Statement 7–3. In patients with MBS treated with plastic stent




Agreement: A, 61%; B, 39%; C, 0%; D, 0%
Stent dysfunction, due to either stent occlusion or migration,
is a potentially serious adverse event (AE) that can result in
life-threatening cholangitis. The optimal surveillance strategy to
prevent or detect early recurrent biliary obstruction (RBO) is
yet to be determined due to the limited number of studies di-
rectly addressing this question.35–37 At the minimum, we recom-
mend that all patients receive education so as to recognize the
signs and symptoms of RBO and the importance of seeking
early medical intervention.
Two main post-stent placement follow-up strategies have been
described.
Planned stent exchange. Planned stent exchange is utilized for
all patients with BBS and can be considered in patients with MBS
treated with PS if close clinical follow up is not available and/or if
life expectancy is greater than 3 months.
On-demand endoscopic intervention. In this strategy, ERCP
is performed when signs of RBO are present. Monitoring strate-
gies to detect early RBO have not been well studied and are mostly
based on empiric evidence and extrapolation from the published
literature. Furthermore, the management approach is dependent
on local resources (availability and cost of laboratory and imaging
evaluations) and patient factors (distance a patient has to travel for
follow-up visits).38 Possible monitoring options include outpatient
clinic visits with evaluation of liver chemistry, with or without
supplemental periodic remote monitoring of liver chemistry. When
physical examination or liver chemistry suggests possible stent
dysfunction, transabdominal ultrasound and/or plain abdominal
film can be performed to assess stent position and to evaluate for
the presence or absence of pneumobilia. The absence of pre-
existing pneumobilia may indicate stent occlusion. On-demand en-
doscopic intervention is the preferred strategy in patients with
MBS treated with self-expandable metallic stents (SEMS). On-
demand stent exchange can be also considered in patients with
MBS treated with PS if close clinical follow up is available
and/or if the patient has a life expectancy of less than 3 months.
However, this approach is not recommended in those without full
knowledge of the signs and symptoms of cholangitis because de-
layed re-intervention can lead to serious consequences.
CQ8. When should endoscopic ultrasound-guided biliary
drainage be considered?.
Statement 8. Where expertise is available, EUS-BD may be an
option in these situations: (i) failed ERCP, (ii) Post-surgical
Y Nakai et al. International consensus for DBS
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anatomy, and (iii) difficult biliary cannulation.
Evidence level: B
Recommendation: 1
Agreement: A, 67%; B, 33%; C, 0%; D, 0%
Transpapillary biliary stent placement is the mainstay of
endoscopic management of DBS. ERCP can be technically dif-
ficult or may fail to achieve biliary drainage due to duodenal ob-
struction by benign or malignant pathologies, periampullary
tumor involvement, the presence of a periampullary diverticu-
lum, or surgically altered anatomy. Although surgical or percuta-
neous techniques have long been utilized in these situations, the
development of EUS-BD has provided a less invasive
therapeutic approach. EUS-BD may be categorized according
to the route of approach and site of biliary drainage:
choledochoduodenostomy, hepaticogastrostomy (HGS), rendez-
vous technique and antegrade biliary stenting. Initially, PS were
the only device used in EUS-BD. Over the last decade, SEMS
have become an option for EUS-BD.33 Recently, the use of lu-
men apposing metal stents has been reported for
choledochoduodenostomy, with the advantage of a lower theo-
retical risk of bile leakage.39 In addition, a specially designed
SEMS and PS have been proposed for use in HGS.40,41 The
technique of EUS-BD has not been standardized and can be
complicated by severe AEs such as bile leak and stent disloca-
tion.42 EUS-BD should therefore be performed by experienced
therapeutic endoscopists. A recent consensus guideline
discusses key issues associated with EUS-BD in detail.43
Although there are some reports on the utility of EUS-BD for
hepaticojejunostomy strictures,44 the role of EUS-BD in the
management of BBS requires further study. Given the lack of
standardization of EUS-BD and the potential risk of severe
AEs, PTBD should be considered the standard of care where ex-
pertise in EUS-BD is not available.
Benign biliary stricture
CQ9. What strategy is recommended for benign biliary
stricture?.
Statement 9. Multiple PS or a fully covered SEMS are recom-
mended options for the treatment of benign biliary strictures.
Evidence level: A
Recommendation: 1
Agreement: A, 89%; B, 11%; C, 0%; D, 0%
Endoscopic management is considered as a first-line treatment
for BBS because of its safety, effectiveness, and less-invasive
nature when compared with surgery or percutaneous techniques.
The recently published Asian-Pacific consensus guidelines sum-
marized the endoscopic management of BBS.45 Our proposal for
endoscopic management of BBS is shown in Figure 2. First, a
guidewire should be passed across the stricture. If the stricture
is tight, pre-stenting dilation may be necessary using a bougie
or a balloon dilator. In general, balloon dilation alone or
Figure 2 Treatment algorithm for management of benign biliary stricture. ERCP, endoscopic retrograde cholangio-pancreatography; EUS-BD, EUS-
guided biliary drainage; GW, guidewire; PS, plastic stent; PTBD, percutaneous transhepatic biliary drainage; SEMS, self-expandable metallic stent.
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placement of a single PS is insufficient treatment for BBS,45–47
and placement of multiple large-bore PS has been established as
standard treatment.48,49 The initial reports of uncovered SEMS
for treatment of BBS showed this to be a poor option because
of stent occlusion by ingrowth of reactive tissue, rendering the
stent unremovable.46 Several prospective studies have demon-
strated the utility of fully covered SEMS for the treatment of
BBS.50,51 The use of a fully covered SEMS resulted in a similar
success rate, with fewer procedures needed and shorter proce-
dure duration, when compared with placement of multiple
PS.52–54 Local resources and expertise can guide the decision
to use either multiple PS or fully covered SEMS. In cases with
BBS, fully covered SEMS should be removed after completion
of treatment as per protocol (4–6 months in general or per man-
ufacturer recommendation) to prevent degradation of the cover-
ing membrane and ingrowth of hyperplastic tissue.50 Magnetic
compression anastomosis is also reported as a treatment option
for BBS.55
Malignant biliary stricture
CQ10–1. Which patients require endoscopic biliary drain-
age before surgery?.
Statement 10–1. Pre-operative drainage should not be routinely
performed, but is indicated in patients with cholangitis, in those




Agreement: A, 80%; B, 20%; C, 0%; D, 0%
CQ10–2. What type of stents should be used before sur-
gery?.
Statement 10–2. In patients who require endoscopic drainage be-
fore surgery, a SEMS may be preferred over a PS.
Evidence level: A
Recommendation: 1
Agreement: A, 90%; B, 10%; C, 0%; D, 0%
Currently, routine preoperative biliary drainage (PBD) is not
recommended. A randomized controlled trial (RCT) reported an
increase in perioperative complications when PBD was performed
for patients with MBS due to pancreatic cancer, in whom early sur-
gery was planned. While a subsequent Dutch study56 showed that
the use of fully covered SEMS reduced perioperative AE com-
pared with PS (24% vs 46%), a Korean RCT57 failed to show su-
periority of fully covered SEMS over PS in terms of AE (16.3% vs
16.3%) and re-interventions (14.0% vs 16.3%). This discrepancy
probably arises from the different lead times to surgery: 5 weeks
in the Dutch study and 2 weeks in the Korean study. In clinical
practice, however, surgery is often delayed due to the limited oper-
ation room time. Surgery is also increasingly delayed when neoad-
juvant chemotherapy is employed. Therefore, PBD is required to
treat cholangitis when surgery is delayed due to operation room
unavailability or neoadjuvant chemotherapy. PS may prematurely
occlude delaying surgery or neoadjuvant chemotherapy. PBD
using fully covered SEMS may assure longer stent patency and
be more cost effective.58
CQ11–1. What type of stent is preferred for unresectable
malignant distal biliary stricture?.




Agreement: A, 88%; B, 12%; C, 0%; D, 0%
CQ11–2. What type of metal stent is preferred for
unresectable malignant distal biliary stricture?.
Statement 11–2. A covered SEMS may be preferred over an un-




Agreement: A, 67%; B, 33%; C, 0%; D, 0%
Six RCTs59–64 and two meta-analyses65,66 have compared cov-
ered and uncovered SEMS’s for unresectable malignant DBS
resulting from various pathologies including pancreatic cancer.
The conclusions of the two meta-analyses differed in terms of stent
patency.65,66 However, two RCTs63,64 and subgroup analysis in a
third RCT59 focusing on pancreatic cancer reported longer patency
of covered SEMS. Regarding AE, covered and uncovered SEMS
are comparable. The two meta-analyses reported no difference in
rates of cholecystitis and pancreatitis.65,66 Some endoscopists
avoid covering the cystic duct takeoff to prevent cholecystitis after
covered SEMS placement. Three RCTs showed that covered
SEMS are prone to migration but covered SEMS with anti-
migration features may reduce the risk of migration.64 Finally,
there is no cost effectiveness analysis comparing covered and un-
covered SEMS for unresectable MBS. As the differential cost of
covered SEMS varies by the insurance system and market, the
cost–benefit analysis is likely to vary based on the cost of using
a covered SEMS in each country.
CQ12. What is the impact of chemotherapy on patients
with a biliary stent in situ?.
Statement 12. Chemotherapy does not appear to increase the risk
of stent occlusion, but may increase the stent migration risk in pa-
tients with a biliary stent in situ.
Evidence level: C
Recommendation: No
Agreement: A, 80%; B, 20%; C, 0%; D, 0%
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Data on the effects of chemotherapy on the outcomes of biliary
stents are limited. Theoretically, neutropenia induced by chemo-
therapy can lead to bacterial overgrowth and subsequent
cholangitis. It can also result in tumor shrinkage with partial reso-
lution of biliary strictures leading to stent migration. It has been re-
ported that preoperative chemoradiation therapy in locally
advanced pancreatic cancer67 and chemotherapy in unresectable
pancreatobiliary cancer68 were not associated with increased
stent-related complications. In patients with unresectable pancre-
atic cancer, gemcitabine chemotherapy did not increase stent oc-
clusion or stent-related complications of SEMS. However, stent
migration tended to be higher in the gemcitabine group (17% vs
3%).69 In a further recent, large-scale study of 291 biliary stents
(151 SEMS and 140 PS), stent patency was comparable in cases
with and without chemo (radio)therapy.70 Neoadjuvant treatment
is increasingly utilized in patients with pancreatic cancer without
distant metastasis. SEMS have demonstrated longer stent patency
than PS in this neoadjuvant setting. Overall, regardless of resect-
ability status, a covered SEMS is recommended in terms of stent
patency and cost effectiveness.58
CQ13. What is the recommended endoscopic treatment
for patients with unresectable malignant dual biliary and
duodenal strictures?.
Statement 13. Endoscopic biliary and duodenal metallic stenting
is an option in patients with unresectable malignant dual biliary
and duodenal strictures. EUS-BD is a promising treatment option
for patients with an indwelling duodenal stent.
Evidence level: C
Recommendation: 2
Agreement: A, 50%; B, 45%; C, 5%; D, 0%
The reported rate of combined MBS and gastric outlet obstruc-
tion (GOO) in advanced pancreatic cancer is approximately
30%.71–73 Historically, double bypass surgery was performed;
however, the development of endoscopic interventions allows less
invasive palliation. While endoscopic biliary stent placement is the
standard of care for MBS, endoscopic duodenal stent placement is
performed for GOO in patients with a poor prognosis and surgical
gastrojejunostomy in patients with longer life expectancy. Surgical
gastrojejunostomy is more invasive, but it enables a longer dura-
tion of oral intake.74,75 In patients with combined MBS and
GOO, retrospective studies report that endoscopic double stenting
is associated with a high technical success rate and an acceptable
AE rate.71,76–81 In the presence of a duodenal stent, ERCP is tech-
nically challenging,82 and the long-term outcomes are subopti-
mal.83 EUS-BD is increasingly reported as a rescue therapy for
failed ERCP. GOO is one of the major causes of ERCP failure.
EUS-BD, and especially EUS-HGS, which results in bile drainage
away from the duodenal stent, may potentially provide longer bil-
iary stent patency84,85 and may be an alternative to transpapillary
stenting in patients with combined MBS and GOO. Meanwhile,
the trans-gastric approach is reportedly associated with a higher
risk of AEs.86 The procedure selected should therefore be deter-
mined by local expertise.
CQ14.What are adjunctive endoscopic treatments for ma-
lignant distal biliary stricture?.
Statement 14. Endo-biliary photodynamic therapy (PDT), radio-
frequency ablation (RFA) and drug-eluting stents (DES) are con-
sidered investigational therapies for malignant DBS.
Evidence level: B (PDT), C (RFA), D (DES)
Recommendation: 2
Agreement: A, 85%; B, 15%; C, 0%; D, 0%.
Adjunctive endoscopic therapy for unresectable malignant DBS
includes intraductal PDT, RFA, and DES,87 of which the first two
are more promising therapies. PDT, primarily used for cholangio-
carcinoma, is a two-step process in which a photosensitizing drug
having affinity for neoplastic tissue (photosensitizer) is adminis-
tered, followed by selective tumor irradiation with light of a de-
fined wavelength (intraductal laser photo-radiation). The
interaction between light and photosensitizing agent causes tumor
cell death due to the formation of oxygen free radicals. PDT has
been reported to increase stent patency, quality of life, and sur-
vival.88–91 The major drawback is systemic photosensitivity,
which occurs in 10% of cases. Intraductal RFA is primarily used
in MBS (cholangiocarcinoma or pancreatic cancer) prior to stent
placement.92 It has high technical success rates and an acceptable
safety profile.93 As biliary RFA locally ablates the tumor, it is ex-
pected to improve stent patency. It reportedly provides similar sur-
vival to PDT, with a good cost effectiveness profile and avoidance
of photosensitivity.94 Intraductal RFA has also been reported to be
useful in treating tissue ingrowth or overgrowth resulting in occlu-
sion of biliary SEMS.95–98 RCTs are required to further assess the
efficacy of adjunctive endoscopic therapies.
Table 2 Definition of causes of recurrent biliary obstruction
Cause of recurrent biliary obstruction Definition
Tissue ingrowth/mucosal hyperplasia Growth of tumor or hyperplastic mucosa into the lumen of SEMS
Tissue overgrowth Tumor or tissue growth beyond the ends of SEMS
Sludge, hemobilia, and food impactionOcclusion of stent lumen by biliary sludge accumulation, clots, and food impaction
Bile duct kinking Obstruction at a proximal or distal end of SEMS due to an angulated bile duct
Stent kinking Obstruction of stent lumen due to sharp bending of a SEMS because of an angulated bile duct or tumor growth
Stent collapse Collapse of stent structure due to tumor growth or other causes (compression by another stent etc.)
SEMS, self-expandable metallic stent.
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Management of recurrent biliary obstruction and other
complications. The current literature assesses numerous vari-
ants of biliary stents that have occluded or malfunctioned, making
inter-study comparisons difficult. For this consensus guideline, we
chose the term RBO, which can result from either stent occlusion
or migration, as described in the Tokyo Criteria 201499 and de-
fined it as the recurrence of jaundice and/or cholangitis following
stent insertion. Causes of stent occlusion may be tumor-related
(tissue ingrowth and overgrowth) or non-tumor related (sludge,
food impaction, mucosal hyperplasia, hemobilia, and kinking of
the bile duct). The definition of each cause of stent occlusion is
shown in Table 2.
Complications other than RBO are also clinically important as
they may necessitate additional interventions or hospitalization
and may significantly impair the patient’s quality of life. Stent-
related complications include pancreatitis, cholecystitis, non-
occlusion cholangitis, bleeding, ulceration, penetration, perfora-
tion, and complications associated with the stent placement proce-
dure (perforation, desaturation, aspiration pneumonia, etc.).
CQ15.What is the approach to cholangitis in patients with
an indwelling biliary stent?.
Statement 15. Cholangitis in patients with an indwelling biliary




Agreement: A, 100%; B, 0%; C, 0%; D, 0%
Patients with an indwelling biliary stent may present with symp-
toms of cholangitis such as fever, pain, and jaundice. RBO is not
uncommon in patients with an indwelling biliary stent who present
with acute cholangitis. Careful physical examination as well as
cross-sectional imaging are recommended prior to endoscopic pro-
cedures. Cholangitis may be life threatening if untreated and may
require early re-intervention to resolve RBO. The therapeutic ap-
proach to cholangitis is determined by an evaluation of the etiol-
ogy and severity.
CQ16. What management is recommended for abdominal
pain in patients with an indwelling biliary stent?.
Statement 16. In a patient with an indwelling biliary stent who




Agreement: A, 80%; B, 20%; C, 0%; D, 0%
Patients may develop delayed stent-related complications. The
complication, as well as the time point at which it occurs, relates
to the type of stent used (plastic vs SEMS;100 covered vs uncov-
ered SEMS).66 Some of the complications that can manifest as ab-
dominal pain are proximal or distal migration with or without
biliary obstruction, impaction, or perforation.
A plain radiograph of the abdomen only allows assessment of
stent position in a 2-D plane. This might be useful if the stent
has migrated significantly (e.g. a migrated PS to the colon101) or
if a perforation has occurred as suggested by extraluminal gas.
The sensitivity of plain X-ray is low, however, and the study
may not detect retroperitoneal perforation. The optimal imaging
modality to investigate abdominal pain in a patient with an in-
dwelling stent is CT. CT accurately defines biliary stent position
and the presence of biliary dilatation and also detects, with high
sensitivity, the presence of free gas (both intra- and retroperito-
neal). Contrast-enhanced CT better defines stent position in rela-
tion to the surrounding organs and vasculature and may
demonstrate a cause for abdominal pain other than stent dysfunc-
tion (e.g. mesenteric ischemia from vascular occlusion).102,103
While CT is associated with a significant cost, radiation exposure,
and the potential for contrast-associated complications, it has dis-
tinct advantages over plain radiography and endoscopic assess-
ment (which is relatively invasive) and represents the best
modality for initial evaluation.
If no cause for abdominal pain has been determined after appro-
priate imaging, the possibility of stent-related mucosal ulceration
should be considered and endoscopy should be performed.104 Oc-
cluded or migrated plastic biliary stents can be readily removed
and can be replaced. The removal of a SEMS may be challeng-
ing.104 If a SEMS is found to have migrated distally and is causing
mucosal ulceration, the intra-luminal section may be trimmed.104–
106 Further details on the management of SEMS dysfunction are
discussed later.
CQ17. What strategy is recommended for the prevention
and management of stent migration?.
Statement 17. To reduce the risk of migration of covered metal
stents, partially covered metal stents or fully covered metal stents
with special anti-migration design can be used.
Evidence level: C
Recommendation: 2
Agreement: A, 74%; B, 26%; C, 0%; D, 0%
Compared with PS, SEMS have a larger diameter and in general
offer a longer duration of stent patency.100 For benign DBS, a cov-
ered SEMS is preferred to uncovered SEMS as the stent needs to
be removed after stricture resolution. However, stent migration is
a key disadvantage of covered SEMS. To reduce the risk of stent
migration, partially or fully covered SEMS with special anti-
migration design features may be used, although there is a paucity
of supporting data. Partially covered SEMS have bare ends, which
embed into the biliary epithelium, thereby preventing migration.
Different designs of fully covered SEMS are currently available.
Anti-migration features include anchoring flaps, flared ends, or
differential radial expansive forces.107 There are few well-
designed comparative studies, however, to determine which design
works best. One randomized study108 showed that a stent with an
anti-migration flap migrated less often than a flared-end stent. A
double pigtail PS may be deployed within a fully covered SEMS,
overlapping its ends, thereby serving as an anchor.108
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CQ18. What complications may occur after biliary
stenting, other than recurrent biliary obstruction?.
Statement 18. Biliary stent-related AEs other than RBO include
pancreatitis, cholecystitis, bleeding, ulceration, non-occlusive
cholangitis, penetration, and perforation.
Evidence level: A
Recommendation: No
Agreement: A, 100%; B, 0%; C, 0%; D, 0%
Biliary stent-related AEs other than RBO can diminish the qual-
ity of life of patients with either MBS or BBS and may necessitate
the interruption of chemotherapy, potentially reducing survival of
patients with MBS. Physicians should be aware of the risk factors
for and the management of stent related AEs. The rates of post-
procedure pancreatitis were 0–5.1% in SEMS and 0–12.5% in
PS.100 The risk factors for pancreatitis were the use of SEMS,
non-pancreatic cancer, and SEMS with high axial force.109,110
The rates of cholecystitis was 0–12.2% in metal stents and 0–
8.9% in PS.100 The risk factors for cholecystitis after MS place-
ment were tumor involvement to the cystic duct, gallstones, and
SEMS with high axial force.111–113
CQ19. When is removal of a metallic stent indicated?.
Statement 19–1. SEMS removal or replacement should be con-
sidered if stent-related complications occur.
Evidence level: C
Recommendation: 1
Agreement: A, 100%; B, 0%; C, 0%; D, 0%
Statement 19–2. Where an uncovered SEMS or partially covered
SEMS has been erroneously placed in a patient with BBS, endo-
scopic removal should be considered as soon as possible.
Evidence level: C
Recommendation: 1
Agreement: A, 90%; B, 10%; C, 0%; D, 0%
In cases of RBO and stent-related complications, stent removal
and/or replacement should be considered whenever possible. Re-
moval of SEMS, particularly uncovered SEMS, can be technically
difficult.114–116 The approach to RBO in patients with distal MBS
depends on the etiology. Placement of a fully covered SEMS
within an uncovered SEMS, obstructed by tumor ingrowth, is rec-
ommended (stent in stent technique).117–119 An obstructed fully
covered SEMS is best managed by stent removal and placement
of a new fully covered SEMS rather than the stent-in-stent tech-
nique or attempts at clearance by balloon sweeping.120
A fully covered SEMS is a treatment option for BBS (see State-
ment 9). Uncovered or partially covered SEMS may occlude due
to tissue hyperplasia through the stent mesh. Stent embedment oc-
curs within 1 week making removal difficult or impossible. There-
fore, uncovered or partially covered SEMS should not be used for
BBS. If one of these SEMS variants has been erroneously placed,
endoscopic removal should be considered as soon as possible. The
stent-in-stent technique utilizing a fully covered SEMS may be
useful.121
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